Novo Nordisk stock pops on Phase 1 data for new weight loss drug amycretin
Novo Nordisk's (NVO) stock was up more than 12% in pre-market trading Friday on news the company's latest weight loss product delivered favorable results. The new drug, amycretin, similar to the company's blockbuster weight loss and diabetes drugs Wegovy and Ozempic,
Novo Nordisk next-gen shot shows 22% weight loss in early results
One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their weight in 36 weeks, according to early-stage trial results on Friday, boosting the drugmaker's shares.
Novo Nordisk amycretin data helps rebut concerns, says BofA
After Novo Nordisk (NVO) reported that subcutaneous amycretin demonstrated up to 22% absolute weight loss at 36-weeks in a Phase 1/2a trial,
Novo Nordisk Jumps On Experimental Weight-Loss Drug Trial Results
Novo Nordisk reported strong early-stage results for its once-a-week obesity drug. Early Friday, Novo Nordisk stock jumped. Eli Lilly fell.
Novo Nordisk shares pop 9% on early-stage weight loss drug trial results
The Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug.
Novo Nordisk shares jump on phase 1b/2a subcutaneous amycretin trial results
Novo Nordisk (NVO) announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist
Novo Nordisk Obesity Drug Achieves Up to 22% Weight Loss in Clinical Trial
Novo Nordisk's (NVO) said Friday that its investigative weight loss drug, amycretin, led to a body weight reduction of up to 22% in an early-stage trial. The maker of obesity drug Wegovy and diabetes treatment Ozempic said its phase 1b/2a trial covered 125 overweight people.
Building a better future: Clinton-Peabody's multimillion-dollar redevelopment project begins Phase 1
The redevelopment will be in five phases. Once completed, it'll have 350 total mixed-income apartments, a renovated community ...
What's the US-China Phase 1 trade deal signed in 2020?
U.S. President Donald Trump has directed federal agencies to assess China's performance under the Phase 1 trade deal that he ...
manilatimes1d
SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy
A live question and answer session will follow the formal presentations. A replay of the call will be available in the ...
Corvus announces data from cohort 2 of Phase 1 trial of Soquelitinib
Corvus Pharmaceuticals (CRVS) announced new interim data from the randomized, double-blind, placebo-controlled Phase 1 clinical trial ...
Wall Street Breakfast Podcast: Allurion Soars On Balloon And GLP-1 Study Plans
Allurion stock soars on weight-loss therapy update. Stardust Power breaks ground on Oklahoma lithium refinery. OpenAI ...
Phase 1 of Israel-Hamas deal to begin Sunday
Former Deputy National Security adviser Victoria Coates analyzes the implications of the cease-fire deal for Gaza and Israel on ‘Fox & Friends Weekend.’ ...
Factbox-What's the US-China Phase 1 Trade Deal Signed in 2020?
In 2020, China imported $135 billion of U.S. goods, and a year later, it bought $178 billion, according to data from Chinese ...
Novo Nordisk stock pops on phase I data for new weight-loss drug amycretin
Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 ...
FierceBiotech1d
Analysts 'highly encouraged' by TREM2 reduction seen in Vigil's phase 1 Alzheimer's data
Vigil Neuroscience has reported early clinical data on its Alzheimer’s disease candidate, positioning the biotech to advance its small molecule in the footsteps of AbbVie and Alector’s failed rival ...